Commitments and Contingencies (Details Narrative)										1 Months Ended	2 Months Ended		3 Months Ended	4 Months Ended	12 Months Ended
	Oct. 30, 2015 USD ($)	Aug. 31, 2015 USD ($)	Aug. 18, 2015 USD ($) shares	Aug. 18, 2015 USD ($) shares	Jan. 27, 2015 USD ($)	Nov. 11, 2014 USD ($)	Oct. 15, 2014 USD ($)	Jun. 27, 2014 USD ($)	Mar. 10, 2010 USD ($)	Dec. 31, 2015 USD ($) shares	Aug. 17, 2015 USD ($)	Aug. 16, 2015 USD ($)	Dec. 31, 2015 USD ($) shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2015 CAD	Dec. 31, 2014 USD ($) shares	Sep. 30, 2014 shares	Dec. 31, 2013 shares
Cash compensation expense															$ 117,000
Stock options to purchase | shares										251,823,581			251,823,581	251,823,581	251,823,581		25,716,668	25,716,668	5,166,668
Minimum annual royalty payment amount															$ 70,000
Minimum amount to be spent to advance the ampakine compounds															250,000
Clinical study and research total cost					$ 50,579
Estimated cost expected	$ 558,268
Principal cash obligations and commitments										$ 3,641,259			$ 3,641,259	$ 3,641,259	3,641,259
Neuroscience and Mental Health Institute at University of Alberta [Member]
Research grants award amount															110,000
Additional cost budgeted under research grant															64,000
Funding cash installments															16,000
Payments to patent costs															15,000
Underwrite additional budgeted costs															15,000
Research consideration total															$ 64,000
Foreign conversion exchange rate										0.7548			0.7548	0.7548	0.7548
Neuroscience and Mental Health Institute at University of Alberta [Member] | CAD [Member]
Research grants award amount | CAD																CAD 146,000
Additional cost budgeted under research grant | CAD																85,000
Funding cash installments | CAD																21,000
Payments to patent costs | CAD																20,000
Underwrite additional budgeted costs | CAD																CAD 20,000
Foreign conversion exchange rate										1.00			1.00	1.00	1.00
Employment and Consulting Agreements [Member]
Cash compensation expense															$ 150,000		$ 25,000
University Of Illinois 2014 Exclusive License Agreement [Member]
Minimum annual royalty payment amount															$ 100,000
License agreement effective date								Sep. 18, 2014
License fee								$ 25,000
Outstanding patent costs								$ 15,840
Percentage of royalty on net sale															4.00%	4.00%
Percentage of payment on sub licensee revenue															12.50%	12.50%
University Of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After Closing Of First Patient Product Phase Two Human Clinical Study [Member]
Payment for sale of product															$ 75,000
University Of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After Closing Of First Patient Product Phase Three Human Clinical Trial [Member]
Payment for sale of product															350,000
University Of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After First New Drug Application Filing [Member]
Payment for sale of product															500,000
University Of Illinois 2014 Exclusive License Agreement [Member] | Due Within Twelve Months After First Commercial Sale Of Product Member [Member]
Payment for sale of product															1,000,000
University Of Illinois 2014 Exclusive License Agreement [Member] | ResearchAndDevelopmentExpenses [Member]
Minimum annual royalty payment amount													$ 250,000		100,000
Maximum [Member] | University Of Illinois 2014 Exclusive License Agreement [Member]
Minimum annual royalty payment amount															100,000
Maximum [Member] | First Sale Of Product [Member] | University Of Illinois 2014 Exclusive License Agreement [Member]
Minimum annual royalty payment amount															150,000
Maximum [Member] | First Commercial Sale Of Product [Member] | University Of Illinois 2014 Exclusive License Agreement [Member]
Minimum annual royalty payment amount															200,000
Richard Purcell [Member] | DNA Healthlink, Inc [Member]
Cash fee							$ 12,500
Mr. Manuso [Member]
Cash compensation expense			$ 375,000											$ 146,060
Increase annually upon the first anniversary			$ 450,000
Stock options to purchase | shares			85,081,300	85,081,300
Purchase newly issued securities			$ 250,000
Automobile lease expenses			16,000
Maximum health coverage amount per month			1,000
Proceeds from offering financing debt			2,000,000
Health plan for employees expense			1,200
Mr. Manuso [Member] | Minimum [Member]
Bonuses			100,000	$ 100,000
Mr. Manuso [Member] | Maximum [Member]
Bonuses			$ 300,000	300,000
Dr. Arnold S. Lippa [Member]
Cash compensation expense				300,000										118,439
Increase annually upon the first anniversary				$ 375,000
Stock options to purchase | shares			10,000,000	10,000,000
Automobile lease expenses				$ 12,000
Maximum health coverage amount per month				1,000
Employee health plan				1,200
Proceeds from offering financing debt				2,000,000
Dr. Arnold S. Lippa [Member] | Minimum [Member]
Bonuses			$ 75,000	75,000
Dr. Arnold S. Lippa [Member] | Maximum [Member]
Bonuses			$ 150,000	150,000
President And Chief Executive Officer [Member]
Cash compensation expense												$ 19,758
Mr Margolis And Mr Weingarten [Member]
Cash compensation expense				$ 195,000						$ 159,540	$ 31,612
Stock options to purchase | shares			10,000,000	10,000,000
Automobile lease expenses				$ 9,000
Maximum health coverage amount per month				1,000
Employee health plan				1,200
Proceeds from offering financing debt				2,000,000
Mr Margolis And Mr Weingarten [Member] | Minimum [Member]
Bonuses			$ 65,000	65,000
Mr Margolis And Mr Weingarten [Member] | Maximum [Member]
Bonuses			$ 125,000	$ 125,000
Mr Margolis [Member]
Cash compensation expense										79,770	15,806
Mr Weingarten [Member]
Cash compensation expense											$ 15,806
Biovail [Member]
Reimbursement related expenses									$ 15,000,000
Payments for future potential									$ 15,150,000
Sharp Clinical Services, Inc [Member]
Estimated cost expected		$ 45,041
Budgeted cost		$ 109,833
February 5, 2016 [Member]
Due and owing for unpaid services rendered										$ 146,000			$ 146,000	$ 146,000	$ 146,000
Former Director [Member]
Unpaid consulting compensation						$ 24,000